SARS-Associated Coronavirus Spike Mosaic S(M)
recombinant, E. coli
For in vitro use only!
Shipping: shipped on gel packs
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 38 kDa
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 25 mM Tris-HCl, 0.4% sarcosyl, 0,25% Triton X-100 and 50% glycerol)
Recombinant SARS-ACSM Antigen may be used in ELISA and Western blots, excellent for detection of SARS with minimal specificity problems.
SARS-ACSM contains the middle section of the Spike protein immunodominant fragments, amino acids: 408-470, 540-573. SARS-ACSM is purified by proprietary chromatographic techniques.
Background: The spike (S) glycoprotein of coronaviruses mediates viral entry into host cells. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. It is a type 1 viral fusion protein that characteristically contains two heptad repeat regions, denoted HR-N and HR-C, that form coiled-coil structures within the ectodomain of the protein. Previous studies have shown that the two heptad repeat regions can undergo a conformational change from their native state to a 6-helix bundle (trimer of dimers), which mediates fusion of viral and host cell membranes .
Specificity: Immunoreactive with sera of SARSinfected individuals.
BIOZ Product Citations:
Please click the arrow on the right to expand the citation list. Click publication title for the full text.
Xu et al. (2004) Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43:14064.
Hsu et al. (2004) Immunological, structural, and preliminary Xray diffraction characterizations of the fusion core of the SARScoronavirus spike protein. Biochem. Biophys. Res. Commun. 324:761.
He et al. (2004) Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173:4050.
Bukreyev et al. (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 363:2122.
Hua et al. (2004) Identification of two antigenic epitopes on SARS-CoV spike protein. Biochem. Biophys. Res. Commun. 319:929.
Bosch et al. (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA. 101:8455.